Technologies
PDF


WARF: P160176US02

  • Patent applied for.

Compound Combination Targets Bacterial Virulence


INVENTORS -

Helen Blackwell, Michael Welsh

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing small molecule cocktails shown to be more effective than single compounds at inhibiting quorum sensing in P. aeruginosa and other bacteria.
OVERVIEWMany common bacterial pathogens delay virulence factor production until there is a sufficient number of cells that – working together – can overwhelm a host’s defense. To coordinate such an attack, some species use a method of cellular communication called quorum sensing (QS). Because of this association with virulence, QS systems are promising antivirulence targets and compounds capable of inhibiting QS are being investigated to fight dangerous bacteria.

A prime example is Pseudomonas aeruginosa, a highly adaptable species that commonly affects immunocompromised patients (e.g., those suffering from HIV, burns or chronic wounds) and is the leading cause of hospital-acquired pneumonia. It uses three independent QS systems (Las, Rhl, Pqs) to establish and maintain infection. Up to this point, strategies to block QS in this bacterium have targeted only one system at a time.

UW–Madison researchers have found that this singular approach is often ineffective in the type of nutrient-deficient environments (esp. low iron and phosphate) characteristic of human infections.
THE INVENTIONThe researchers have discovered that two lead compounds (E22/M64) can be combined to target multiple QS pathways at the same time (Rhl/Pqs), resulting in enhanced activity against P. aeruginosa and potentially other pathogens. This new cocktail approach is superior because it attenuates virulence factor production across a range of relevant environments where single compounds fail.
APPLICATIONS
  • New antibacterial compositions, coatings and packaging to control P. aeruginosa infections (e.g., treating cystic fibrosis patients) and potentially other pathogens
KEY BENEFITS
  • Novel combination strategy
  • Utilizes two known small molecules
STAGE OF DEVELOPMENTThe researchers used chemical probes to evaluate the contribution of each QS pathway to virulence in wild-type P. aeruginosa under defined environmental conditions. The results indicate that two of the pathways (Rhl and Pqs) drive virulence factor production in phosphate- and iron-limiting environments. From this they produced a cocktail comprising E22/M64 and demonstrated attenuated virulence in environments where other inhibitors fail.
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Technologies
Publications
  • Welsh M.A., Eibergen N.R., Moore J.D. and Blackwell H.E. 2015. Small Molecule Disruption of Quorum Sensing Cross-Regulation in Pseudomonas aeruginosa Causes Major and Unexpected Alterations to Virulence Phenotypes. J Am Chem Soc. 137, 1510-1519.
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or (608) 265-9861.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.